时间：2026年10月17日
Date: Oct. 17, 2026
Masimo（Danaher 旗下）smartSET™获 FDA 510(k)批准：脉搏血氧平台新增“心房颤动检测”，AI 床边监护再进一步
Masimo’s smartSET™Wins FDA 510(k) Clearance for First-of-Its-Kind Atrial Fibrillation Detection—AI-Powered Pulse Oximetry Now Flags AFib and Opioid-Related Risks at the Bedside
摘要 :
2026 年10 月17 日,Masimo(Danaher 旗下公司)宣布其Radius VSM®可穿戴监护仪新增房 颤(AFib)检测功能并获美国FDA 510(k)批准——使smartSET™成为业内首个同时具备房颤检测与 此前已获批的AI 驱动阿片诱导呼吸抑制(OIRD)检测功能的脉搏血氧平台｡
smartSET 基于Masimo SET®超过35 年的信号处理创新,将连续监护从“可靠测量”推进到“临床 洞察”｡在临床验证中,基于PPG 的房颤检测功能以心电判读为金标准,灵敏度达97%､特异性达 100%,可提示疑似房颤心律､建议进一步评估——鉴于65 岁以上患者房颤患病率超过10%且常未被 确诊,这一功能意义重大｡AI 驱动的OIRD 检测功能则实时分析血氧饱和度( ((SpO_{2})) )､脉率与灌注指 数(Pi)以评估阿片过量风险,对应“每10 名接受阿片类药物的手术患者中就有1 人出现相关不良事 件”的循证数据｡首席医疗官Basil Matta 博士表示,将AI 模式识别引入脉搏血氧工作流,可帮助临 床团队更早发现细微的生理变化;总裁Tim Benner 则称这一功能组合是“重大飞跃”,让严重患者风 险在症状升级前即被看见｡Masimo 估计其SET®技术每年在全球超过2 亿患者身上使用｡
Summary :
On October 17, 2026, Masimo, a Danaher company, announced FDA 510(k) clearance for atrial fibrillation (AFib) detection on its Radius VSM® wearable monitor—making smartSET™the industry’s first pulse-oximetry platform to pair AFib detection with previously cleared AI-enabled opioid-induced respiratory depression (OIRD) detection.
smartSET builds on more than 35 years of Masimo SET® signal-processing innovation to extend continuous monitoring from reliable measurement to clinical insight. In validation testing, the PPGbased AFib capability demonstrated 97% sensitivity and 100% specificity against ECG-based ground truth, flagging rhythms suggestive of AFib for further evaluation—relevant because AFib affects more than 10% of patients over 65 and often goes undiagnosed. The AI-enabled OIRD capability analyzes (SpO_{2}) , pulse rate and perfusion index in real time to assess opioid-overdose risk, addressing evidence that 1 in 10 surgical patients receiving opioids experiences an opioid-related adverse event. Chief Medical Officer Dr. Basil Matta said bringing AI-driven pattern recognition into the pulse-oximetry workflow helps clinicians see subtle physiological shifts earlier, while President Tim Benner called the addition “a major leap forward” for earlier visibility into serious patient risks. Masimo estimates its SET® technology is used on more than 200 million patients worldwide each year.
入选理由 :
这是周末唯一一篇全球500 强企业新闻稿,却分量十足:一张510(k)批准书把传统血氧仪变成“床边 AI 哨兵”——全球首创的房颤检测(灵敏度97%､特异性100%)叠加阿片呼吸抑制风险评估,同时 踩中可穿戴监护､AI 诊断与患者安全三大热点,个性鲜明､独此一家｡
Why Selected:
The weekend’s only Global 500 release is also one of the most consequential: a 510(k) that turns the humble pulse oximeter into an AI sentinel—combining first-of-its-kind AFib detection (97% sensitivity, 100% specificity) with OIRD risk scoring, squarely hitting the intersection of wearable monitoring, AI diagnostics and patient safety.
浏览量：166,000
Views：166,000
独立IP：48,900
Unique Clicks ：48,900
